Delta-fly pharma inc.: notice of initiation of phase iii pivotal comparative clinical trial of dfp-14323

Tokushima, japan--(business wire)--we are excited to share our latest development status. as presented at 2022 asco annual meeting on june 6, 2022, dfp-14323 in combination with afatinib (20 mg/day) in stage iii/iv non-small cell lung cancer patients with epidermal growth factor receptor (egfr) mutation positive in a phase ii clinical trial, has demonstrated fascinating longer median progression-free survival (mpfs; 23.1 months). subsequently, based on these results, we have been in negotiation.
DAL Ratings Summary
DAL Quant Ranking